Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757285 | 1.00 | EGFR (0.39) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6764328 | 0.92 | EGFR (0.39) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6764332 | 0.92 | EGFR (0.39) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6757349 | 0.91 | GPR183 (0.42) | NPC1RAB9AKMT2A | |
| SCHEMBL6757351 | 0.91 | GPR183 (0.42) | NPC1RAB9AKMT2A | |
| SCHEMBL6762218 | 0.91 | MAPT (0.39) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6762217 | 0.91 | MAPT (0.39) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6760418 | 0.90 | EGFR (0.42) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6760417 | 0.90 | EGFR (0.42) | EGFRCCR8MAPTGLASMN1; SMN2 | |
| SCHEMBL6764116 | 0.88 | ALDH1A1 (0.42) | EGFRCCR8MAPTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | EGFR 4879/4885CCR8 4636/4885MAPT 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.